40 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
of the FCPA, UK Bribery Act, any applicable non-U.S. anti-bribery statute or regulation or any locally applicable corruption laws; (iv) made any bribe
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm
”)) or employee; (iii) violated or is in violation of any provision of the FCPA, UK Bribery Act, any applicablenon-U.S. anti-bribery statute or regulation
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
(collectively, the “FCPA”)) or employee; (iii) violated or is in violation of any provision of the FCPA, UK Bribery Act, any applicable non-U.S. anti-bribery
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
or is in violation of any applicable provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any other applicable anti-bribery or anti
424B3
cuw7cunz2rb55ho220
14 Oct 15
Prospectus supplement
12:00am
10-Q
3v6c6b4gv0dsp
18 Dec 14
Quarterly report
12:00am
424B5
ub6h 4ftcvw
22 Oct 19
Prospectus supplement for primary offering
4:24pm
424B5
5ev790lhy67g t7
25 Oct 19
Prospectus supplement for primary offering
12:00am